Your fact-checks will appear here
Ivermectin is approved and used safely in specific human indications, such as onchocerciasis.
Ivermectin dosing for human parasitic infections is weight-based and generally expressed in micrograms per kilogram (mcg/kg); the usual therapeutic range for common infections is about 150–200 mcg/kg ...
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Serious neurologic adverse events (encephalopathy, seizures, coma, persistent coma, ataxia) after ivermectin are uncommon but documented, and risk clusters around particular parasitic coinfections (no...
Documented human cases of ivermectin‑related neurotoxicity are rare but well described in the literature and fall into three broad patterns: mass‑treatment encephalopathies linked to parasitic coinfec...
The FDA‑label prescribing information for STROMECTOL (ivermectin) specifies dosing by indication: a single oral dose of approximately 200 mcg/kg for intestinal strongyloidiasis and approximately 150 m...
Documented instances exist in which people consumed or were treated with veterinary (animal) formulations, and those events prompted poison-control calls, hospitalizations and public health warnings; ...
High or “off‑label” ivermectin dosing raises two linked safety questions: are higher exposures intrinsically toxic, and do specific contexts (co‑infections, genetics, formulations, drug interactions) ...
There are no published human pharmacokinetic (plasma concentration or exposure) thresholds that reliably predict renal adverse events (AEs) after ivermectin; population pharmacovigilance and clinical ...
Standard, single therapeutic oral doses of ivermectin used in humans have not been consistently shown to raise serum creatinine, blood urea nitrogen (BUN), or to reduce glomerular filtration rate (GFR...
Ivermectin is an effective, evidence-based antiparasitic for specific human infections — notably onchocerciasis and strongyloidiasis — when used at approved doses under medical supervision . It is not...
Repeating ivermectin is routine for onchocerciasis (often yearly) and sometimes necessary for strongyloidiasis—especially in immunocompromised patients—but repetition brings predictable risks that can...
Ivermectin in adults is associated with a spectrum of recognized adverse reactions that can be neurological (confusion, seizures, encephalopathy) and allergic or cutaneous (rash, pruritus, severe hype...
Reports and case-series show multiple instances where people ingested veterinary ivermectin formulations — most commonly during the COVID-19 pandemic — producing a spectrum of outcomes from mild gastr...
Ivermectin’s standard, evidence-backed human dosing for parasitic infections is generally in the 150–200 micrograms per kilogram (mcg/kg) single-dose range, with some indications and expert guides ext...
Human prescription ivermectin is supplied as regulated, weight‑based oral tablets or topical formulations at low, controlled strengths for single‑dose or short‑course use (typically ~0.15–0.20 mg/kg f...